Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

 Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

Shots:

  • Abbott to get non-exclusive license rights for Banyan’s TBI biomarkers, including Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) kit to utilize it on its laboratory instruments
  • The focus of the agreement is to develop TBI assessment blood test for the patient with traumatic brain injury in the US and worldwide
  • Banyan BTI is the first blood test used for identification of biomarkers GFAP and UCH-L1 released from the brain and consists of two test kits Banyan GFAP and Banyan UCH-L1 providing ease to physicians to detect TBIs 

Click here to read full press release/ article | Ref: Business Wire | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post